Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial.
Geert Jan BiesselsChloë VerhagenJolien JanssenEsther van den BergBernard ZinmanJulio RosenstockJyothis T GeorgeAnna PasseraSven SchnaidtOdd Erik Johansennull nullPublished in: Diabetes care (2019)
In a large international cardiovascular outcome trial in people with type 2 diabetes and cardiorenal disease, linagliptin did not modulate cognitive decline over 2.5 years.